Related Experiment Video
Updated: Aug 14, 2026

Coupled Assays for Monitoring Protein Refolding in Saccharomyces cerevisiae
Published on: July 9, 2013
RSK2 represses HSF1 activation during heat shock
1Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
Heat shock transcription factor 1(HSF1) activation is a multistep process. The conversion of a latent cytoplasmic form to a nuclear, DNA binding state appears to be activated by nonsteroidal anti-inflammatory drugs. In previous studies, we showed that HSF 1 is phosphorylated by the protein kinase RSK2 in vitro and that this effect is inhibited by nonsteroidal anti-inflammatory drugs at the concentration that leads to the activation of HSF1 in vivo (Stevenson et al 1999). In the present study, using cells from a patient with Coffin-Lowry syndrome (deficient in RSK2), we demonstrate that RSK2 slightly represses activation of HSF1 in vivo at 37 degrees C. In Coffin-Lowry syndrome cells, HSF1-HSE DNA binding activity after treatment with sodium salicylate was slightly higher than that in untreated cells, indicating that although RSK2 is involved in HSF1 regulation, it is not the unique protein kinase that suppresses HSF1-HSE binding activity at 37 degrees C. However, heat shock treatment resulted in significantly higher HSF1-HSE binding activity in Coffin-Lowry syndrome cells as compared with normal controls, suggesting that RSK2 represses HSF1-HSE binding activity during heat shock.
Insights
Heat shock transcription factor 1 (HSF1) activation is regulated by the protein kinase RSK2. RSK2 represses HSF1 DNA binding activity, particularly during heat shock, as shown in Coffin-Lowry syndrome cells lacking RSK2.
Area of Science:
- Molecular Biology
- Cellular Stress Response
Background:
- Heat shock transcription factor 1 (HSF1) activation is a complex process involving its translocation to the nucleus and DNA binding.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to activate HSF1.
- Previous research indicated that RSK2 phosphorylates HSF1 in vitro, an effect inhibited by NSAIDs.
Purpose of the Study:
- To investigate the role of RSK2 in HSF1 activation in vivo.
- To examine HSF1 activation in cells deficient in RSK2, specifically in the context of Coffin-Lowry syndrome.
Main Methods:
- Utilized cell lines from a patient with Coffin-Lowry syndrome (RSK2 deficient).
- Assessed HSF1-HSE DNA binding activity following treatment with sodium salicylate and heat shock.
- Compared HSF1 activation in Coffin-Lowry syndrome cells versus normal control cells.
Main Results:
- RSK2 slightly represses HSF1 activation in vivo at 37°C.
- HSF1-HSE DNA binding activity was slightly elevated in Coffin-Lowry syndrome cells after sodium salicylate treatment compared to untreated cells.
- Heat shock treatment induced significantly higher HSF1-HSE binding activity in Coffin-Lowry syndrome cells than in normal controls.
Conclusions:
- RSK2 plays a role in repressing HSF1-HSE DNA binding activity, especially during heat shock.
- While RSK2 is involved in HSF1 regulation, it is not the sole protein kinase suppressing HSF1-HSE binding at 37°C.
- These findings highlight RSK2 as a key repressor of HSF1 activity under thermal stress.
Related Concept Videos
Homologous Recombination
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Co-activators and Co-repressors
Regulation of the Unfolded Protein Response
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...
Other Stress Responses in Bacteria

